120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
非糖尿病慢性肾脏病中非奈利酮联合达格列净治疗的疗效和安全性：一项单中心回顾性研究
Authors Ma J, Su Q, Wang H, Xu J, Yuan C, Fan G , Ying J, Bian X
Received 3 September 2025
Accepted for publication 20 January 2026
Published 24 January 2026 Volume 2026:20 564942
DOI https://doi.org/10.2147/DDDT.S564942
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Solomon Tadesse Zeleke
Jianwei Ma,1,2,* Qin Su,1,* Hanlu Wang,1 Jiayan Xu,1,3 Chenyi Yuan,1 Guicai Fan,1,3 Jiapei Ying,1 Xueyan Bian1
1Department of Nephrology, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, People’s Republic of China; 2Department of Clinical Medicine, Tongji University School of Medicine, Shanghai, 200092, People’s Republic of China; 3Health Science Center, Ningbo University, Ningbo, 315211, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xueyan Bian, Department of Nephrology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Haishu District, Ningbo, 315010, People’s Republic of China, Email fyybianxueyan@nbu.edu.cn
Background: The combination of non-steroidal mineralocorticoid receptor antagonists (nsMRAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors has shown renoprotective benefits in diabetic kidney disease; however, their synergistic effects in non-diabetic chronic kidney disease (CKD) remain underexplored. This study evaluated the efficacy and safety of finerenone combined with dapagliflozin versus dapagliflozin monotherapy in patients with non-diabetic CKD.
Methods: A single-center, retrospective cohort study was conducted on 121 patients with biopsy- or clinically confirmed non-diabetic CKD treated with either dapagliflozin alone (n = 77) or in combination with finerenone (n = 44) for ≥ 6 months. Propensity score matching (PSM) yielded 33 well-balanced pairs. The primary outcomes were changes in the urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) over 6 months. Secondary outcomes included Blood Pressure, biochemical parameters, and treatment-related adverse events. Repeated-measures ANOVA and mediation analyses were used to assess longitudinal changes and mechanistic relationships.
Results: Finerenone Combined with Dapagliflozin therapy significantly enhanced UACR reduction at 3 months (median 63.4% vs 47.8%, P = 0.007) and 6 months (66.9% vs 40.8%, P = 0.002), compared with dapagliflozin alone, with a higher proportion of patients achieving ≥ 50% reduction (84.9% vs 45.5%, P < 0.001). The eGFR was preserved or improved with combination therapy (+2.06% vs – 5.08%, P < 0.001), whereas dapagliflozin alone therapy was associated with a decline. Mediation analysis indicated that early UACR reduction explained only 1.45% of the treatment effect on eGFR changes, suggesting albuminuria-independent mechanisms. The incidence of adverse events, including hyperkalemia, did not differ significantly between the groups, and all events were mild and manageable.
Conclusion: Finerenone combined with dapagliflozin yielded superior proteinuria reduction and better preservation of renal function compared with dapagliflozin alone in patients with non-diabetic CKD, without compromising safety. These findings provide real-world evidence for the potential additive renoprotective effects of dual therapy and underscore the need for prospective trials to validate its efficacy in non-diabetic populations.
Keywords: finerenone, dapagliflozin, non-diabetic chronic kidney disease, albuminuria, estimated glomerular filtration rate
1Department of Nephrology, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, People’s Republic of China; 2Department of Clinical Medicine, Tongji University School of Medicine, Shanghai, 200092, People’s Republic of China; 3Health Science Center, Ningbo University, Ningbo, 315211, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xueyan Bian, Department of Nephrology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Haishu District, Ningbo, 315010, People’s Republic of China, Email fyybianxueyan@nbu.edu.cn
Background: The combination of non-steroidal mineralocorticoid receptor antagonists (nsMRAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors has shown renoprotective benefits in diabetic kidney disease; however, their synergistic effects in non-diabetic chronic kidney disease (CKD) remain underexplored. This study evaluated the efficacy and safety of finerenone combined with dapagliflozin versus dapagliflozin monotherapy in patients with non-diabetic CKD.
Methods: A single-center, retrospective cohort study was conducted on 121 patients with biopsy- or clinically confirmed non-diabetic CKD treated with either dapagliflozin alone (n = 77) or in combination with finerenone (n = 44) for ≥ 6 months. Propensity score matching (PSM) yielded 33 well-balanced pairs. The primary outcomes were changes in the urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) over 6 months. Secondary outcomes included Blood Pressure, biochemical parameters, and treatment-related adverse events. Repeated-measures ANOVA and mediation analyses were used to assess longitudinal changes and mechanistic relationships.
Results: Finerenone Combined with Dapagliflozin therapy significantly enhanced UACR reduction at 3 months (median 63.4% vs 47.8%, P = 0.007) and 6 months (66.9% vs 40.8%, P = 0.002), compared with dapagliflozin alone, with a higher proportion of patients achieving ≥ 50% reduction (84.9% vs 45.5%, P < 0.001). The eGFR was preserved or improved with combination therapy (+2.06% vs – 5.08%, P < 0.001), whereas dapagliflozin alone therapy was associated with a decline. Mediation analysis indicated that early UACR reduction explained only 1.45% of the treatment effect on eGFR changes, suggesting albuminuria-independent mechanisms. The incidence of adverse events, including hyperkalemia, did not differ significantly between the groups, and all events were mild and manageable.
Conclusion: Finerenone combined with dapagliflozin yielded superior proteinuria reduction and better preservation of renal function compared with dapagliflozin alone in patients with non-diabetic CKD, without compromising safety. These findings provide real-world evidence for the potential additive renoprotective effects of dual therapy and underscore the need for prospective trials to validate its efficacy in non-diabetic populations.
Keywords: finerenone, dapagliflozin, non-diabetic chronic kidney disease, albuminuria, estimated glomerular filtration rate